[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363648-105":59,"doc-detail-363648-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","targeted-therapy-in-thyroid-cancer-molecular-alterations-and-clinical-management","Targeted therapy in thyroid cancer: molecular alterations and clinical management","","This review summarizes actionable molecular alterations in thyroid cancer and explains how molecular profiling can be translated into practical, subtype-specific targeted treatment strategies for advanced, recurrent, or radioiodine-refractory disease. A narrative synthesis of landmark trials, consensus guidelines, and translational studies categorizes molecular targets by signaling pathways and pathological subtypes (DTC, PTC/FTC, ATC/PDTC, and MTC). Genomic drivers such as BRAF V600E, RET mutations/fusions, and NTRK fusions guide precision selection, while kinase inhibitors and redifferentiation approaches address marker-negative cases. It also highlights emerging combinations involving PI3K/AKT/mTOR and immune checkpoint pathways to overcome resistance.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-therapy-in-thyroid-cancer-molecular-alterations-and-clinical-management/363648/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-therapy-in-thyroid-cancer-molecular-alterations-and-clinical-management/363648.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this review on thyroid cancer therapy?","Question",{"text":113,"@type":114},"It summarizes key actionable molecular alterations in thyroid cancer and discusses how molecular profiling can guide practical, subtype-specific targeted treatment for advanced, recurrent, or radioiodine-refractory disease.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which molecular drivers are highlighted as central to precision treatment?",{"text":118,"@type":114},"The review emphasizes genomic drivers such as BRAF V600E, RET mutations/fusions, and NTRK fusions, and explains how these markers inform targeted inhibitor selection.",{"name":120,"@type":111,"acceptedAnswer":121},"How are treatment options handled for radioiodine-refractory differentiated thyroid cancer without specific markers?",{"text":122,"@type":114},"For cases lacking these specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remain a standard of care for RAIR-DTC.",{"name":124,"@type":111,"acceptedAnswer":125},"Why is early comprehensive genomic profiling, including fusion detection, considered essential?",{"text":126,"@type":114},"It helps optimize treatment selection, address resistance, and expand precision therapy options across different thyroid cancer subtypes, improving the ability to sequence adaptive combination strategies.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},363648,1790553887,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 05 June 2026  \nDOI 10.3389/fendo.2026.1810813  \nOPEN ACCESS  \nEDITED BY  \nHsiang-Chi Huang,  \nNational Cheng Kung University, Taiwan  \nREVIEWED BY  \nMuhammad Babar Imran,  \nPunjab Institute of Nuclear Medicine, Pakistan  \nCarly Barron,  \nUniversity Health Network (UHN), Canada  \n*CORRESPONDENCE  \nYeSheng Zhang  \n[ZhangZongChina666@163.com](ZhangZongChina666@163.com)[ ](ZhangZongChina666@163.com)GuoChao Ye  \n[chaogechina@163.com](chaogechina@163.com)[ ](chaogechina@163.com)†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 13 February 2026  \nREVISED 20 May 2026  \nACCEPTED 26 May 2026  \nPUBLISHED 05 June 2026  \nCITATION  \nYang Y, Zhang Y, Xu Y, Gu X, Lou N and Ye G (2026) Targeted therapy in thyroid cancer: molecular alterations and clinical management.  \nFront. Endocrinol. 17:1810813 .  \ndoi: 10.3389/fendo.2026.1810813  \nCOPYRIGHT  \n© 2026 Yang, Zhang, Xu, Gu, Lou and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeted therapy in thyroid cancer: molecular alterationsand clinical management  \nYiHeng Yang 1†, YeSheng Zhang 2*†, YongCan Xu 1, XiaoXin Gu 3, Neng Lou 1 and GuoChao Ye 1*  \n1 Department of General Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China, 2 Department of General Surgery, Afﬁliated Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, Zhejiang, China,  \n3 Department of General Surgery, Huzhou Central Hospital, Afﬁliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China  \nBackground: This review summarizes key actionable molecular alterations in thyroid cancer and examines how molecular proﬁling can be translated into practical, subtype-speciﬁc targeted treatment strategies for advanced, recurrent, or radioiodine-refractory disease.  \nMethods: A narrative synthesis was performed using evidence from landmark clinical trials, current consensus guidelines, and representative translational studies on thyroid cancer drivers and targeted therapies. Molecular targets were categorized by signaling pathways and pathological subtypes (DTC, PTC/FTC, ATC/PDTC, and MTC), with emphasis on clinical indications, efﬁcacy signals, and toxicity proﬁles.  \nResults: The identiﬁcation of speciﬁc genomic drivers, such as BRAF V600E, RET mutations/fusions, and NTRK fusions, has revolutionized the management of thyroid cancer. Precision highlights include the use of BRAF/MEK inhibitors in BRAF-mutant ATC and highly selective RET or TRK inhibitors for fusion-positive tumors. For cases lacking these speciﬁc markers, VEGFR-targeted multikinase inhibitors (e. g. , lenvatinib) remains the standard of care for RAIR-DTC. Furthermore, “redifferentiation” therapies show promise in restoring radioiodine sensitivity, while emerging pathways like PI3K/AKT/mTOR and immune checkpoints offer new avenues for combination therapy to overcome treatment resistance.  \nConclusions: The therapeutic paradigm in thyroid cancer is shifting from nonselective multikinase inhibition toward molecularly matched, combination-based, and adaptively sequenced strategies . Early and comprehensive genomic proﬁling—including fusion detection—is essential to optimize treatment selection, address resistance, and expand precision therapy options across disease subtypes.  \nKEYWORDS  \nmolecular alterations, precision medicine, radioiodine-refractory thyroid cancer, targeted therapy, thyroid cancer  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \n1 Background  \nThyroid cancer is the mos","cbCais0scH283TTj","https://ap.wps.com/l/cbCais0scH283TTj","pdf",2321372,23,"English","# Background\n# Methods\n# Results\n## Molecular drivers and targeted strategies\n# Conclusions","[{\"question\":\"What is the main purpose of this review on thyroid cancer therapy?\",\"answer\":\"It summarizes key actionable molecular alterations in thyroid cancer and discusses how molecular profiling can guide practical, subtype-specific targeted treatment for advanced, recurrent, or radioiodine-refractory disease.\"},{\"question\":\"Which molecular drivers are highlighted as central to precision treatment?\",\"answer\":\"The review emphasizes genomic drivers such as BRAF V600E, RET mutations/fusions, and NTRK fusions, and explains how these markers inform targeted inhibitor selection.\"},{\"question\":\"How are treatment options handled for radioiodine-refractory differentiated thyroid cancer without specific markers?\",\"answer\":\"For cases lacking these specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remain a standard of care for RAIR-DTC.\"},{\"question\":\"Why is early comprehensive genomic profiling, including fusion detection, considered essential?\",\"answer\":\"It helps optimize treatment selection, address resistance, and expand precision therapy options across different thyroid cancer subtypes, improving the ability to sequence adaptive combination strategies.\"}]","Targeted therapy in thyroid cancer: molecular alterations and clinical management | PDF",1790152393,58,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76dab51c88f72de75581bb2f19565da6.webp",983,1389,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa71aa5883f5f10e6b87c9dc8f2374f0.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0445e144d4ae838b880c9cf5a001950a.webp",981,1386,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d203f4ac5e5089761af53fddde3fdee1.webp",980,1385]